Esmolol and Labetalol in ECT

Comparison of the effectiveness of low-dose Esmolol and Labetalol on changes in heart rate and blood pressure in patients treated with electroshock (ECT)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20160307026950N19

Enrollment

Registered

2020-06-02

Start date

2020-06-21

Completion date

Unknown

Last updated

2022-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Blood Pressure. Condition 2: Heart Rate. Elevated blood-pressure reading, without diagnosis of hypertension Tachycardia, unspecified

Interventions

Intervention 1: Intervention Group A

Labethalol is administered at a dose of 0.2 mg per kg body weight prior to anesthesia. Intervention 2: Intervention group B

Esmolol is injected 0.5 mg per kilogram of body weight prior to anesthesia. Intervention 3: Control group C

Normal saline is injected into the patient as a placebo before injecting the anesthetic.

Eligibility

Sex/Gender

All

Age

13 Years to 19 Years

Inclusion criteria

Inclusion criteria: Candidate for electroshock therapy Range of 13 to 19 years ASA class I and II The patient's consent to participate in the study

Exclusion criteria

Exclusion criteria: Contraindications to the use of Esmolol and Labetalol Previous consumption of beta-blockers Sensitivity to Esmolal and labetalol Asthma and drug allergies History of severe cardiovascular disease, chronic respiratory disease, kidney disease, and liver disease

Design outcomes

Primary

Measure	Time frame
Heart Rate. Timepoint: Before prescribing Esmolal, labetalol, and normal saline, before prescribing anesthesia, just before the ECT, during the shock, 1, 3, 5, 10, and 20 minutes after the shock. Method of measurement: ECG monitoring and Pulse Oximeter.;Systolic Blood Pressure. Timepoint: Before prescribing Esmolol, labetalol, and normal saline, before prescribing anesthesia, just before the ECT, during the shock, 1, 3, 5, 10, and 20 minutes after the shock. Method of measurement: Non-invasive blood pressure measurement.;Diastolic Blood Pressure. Timepoint: Before prescribing Esmolol, labetalol, and normal saline, before prescribing anesthesia, just before the ECT, during the shock, 1, 3, 5, 10, and 20 minutes after the shock. Method of measurement: Non-invasive blood pressure measurement.;Mean Arterial Pressure. Timepoint: Before prescribing Esmolol, labetalol, and normal saline, before prescribing anesthesia, just before the ECT, during the shock, 1, 3, 5, 10, and 20 minutes after the shock. Method of measurement: Non-invasive blood pressure measurement.	—

Measure

Time frame

Heart Rate. Timepoint: Before prescribing Esmolal, labetalol, and normal saline, before prescribing anesthesia, just before the ECT, during the shock, 1, 3, 5, 10, and 20 minutes after the shock. Method of measurement: ECG monitoring and Pulse Oximeter.;Systolic Blood Pressure. Timepoint: Before prescribing Esmolol, labetalol, and normal saline, before prescribing anesthesia, just before the ECT, during the shock, 1, 3, 5, 10, and 20 minutes after the shock. Method of measurement: Non-invasive blood pressure measurement.;Diastolic Blood Pressure. Timepoint: Before prescribing Esmolol, labetalol, and normal saline, before prescribing anesthesia, just before the ECT, during the shock, 1, 3, 5, 10, and 20 minutes after the shock. Method of measurement: Non-invasive blood pressure measurement.;Mean Arterial Pressure. Timepoint: Before prescribing Esmolol, labetalol, and normal saline, before prescribing anesthesia, just before the ECT, during the shock, 1, 3, 5, 10, and 20 minutes after the shock. Method of measurement: Non-invasive blood pressure measurement.

—

Secondary

Measure	Time frame
Oxygen saturation. Timepoint: Before prescribing Esmolol, labetalol, and normal saline, before prescribing anesthesia, just before the ECT, during the shock, 1, 3, 5, 10, and 20 minutes after the shock. Method of measurement: Pulse oximeter.;The duration of the seizure. Timepoint: Beginning to the end of the seizure. Method of measurement: Chronometer.;The duration of anesthesia. Timepoint: Beginning to the end of the anesthesia. Method of measurement: Chronometer.;Recovery time. Timepoint: From the end of anesthesia to full awakening. Method of measurement: Watch.;Nausea and Vomiting. Timepoint: During the stay in the recovery. Method of measurement: Ask the patient about this complication.;Headache. Timepoint: During the stay in the recovery. Method of measurement: Asking from the patient.;Larangospasm. Timepoint: During the stay in the recovery. Method of measurement: Monitoring.	—

Measure

Time frame

Oxygen saturation. Timepoint: Before prescribing Esmolol, labetalol, and normal saline, before prescribing anesthesia, just before the ECT, during the shock, 1, 3, 5, 10, and 20 minutes after the shock. Method of measurement: Pulse oximeter.;The duration of the seizure. Timepoint: Beginning to the end of the seizure. Method of measurement: Chronometer.;The duration of anesthesia. Timepoint: Beginning to the end of the anesthesia. Method of measurement: Chronometer.;Recovery time. Timepoint: From the end of anesthesia to full awakening. Method of measurement: Watch.;Nausea and Vomiting. Timepoint: During the stay in the recovery. Method of measurement: Ask the patient about this complication.;Headache. Timepoint: During the stay in the recovery. Method of measurement: Asking from the patient.;Larangospasm. Timepoint: During the stay in the recovery. Method of measurement: Monitoring.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Mirelahi

Esfahan University of Medical Sciences

zmirelahi1994@gmail.com+98 31 3568 5233

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026